Incyte grants 28,475 stock options to R&D chief

Incyte Corporation reported a new stock option grant to a senior executive.

Rhea-AI Filing Summary

Incyte Corporation reported a new stock option grant to a senior executive. President of R&D Pablo J. Cagnoni received an employee stock option to purchase 28,475 shares of Incyte common stock at an exercise price of $106.21 per share, effective January 16, 2026.

The option was granted at no cost to the executive and is held directly. Beginning January 16, 2026, the award becomes exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years. After this grant, Cagnoni beneficially owns 28,475 derivative securities in the form of these options.

Insider Trade Summary

Grant/Award: 28,475 shares

Grant/Award 1 txn

Insider CAGNONI PABLO J

Role President, R&D

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	28,475	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 28,475 contracts (Direct)

Footnotes (1)

1. F1. Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Incyte (INCY) report for Pablo J. Cagnoni?

Incyte reported that President of R&D Pablo J. Cagnoni received an employee stock option grant covering 28,475 shares of common stock on January 16, 2026.

What is the exercise price of the new Incyte (INCY) stock options granted to Pablo J. Cagnoni?

The employee stock option granted to Pablo J. Cagnoni has an exercise price of $106.21 per share for Incyte common stock.

How do the new Incyte (INCY) options for Pablo J. Cagnoni vest?

The options begin vesting on January 16, 2026 in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years.

How many derivative securities does Pablo J. Cagnoni own after this Incyte (INCY) grant?

Following the reported transaction, Pablo J. Cagnoni beneficially owns 28,475 derivative securities, all from this employee stock option grant.

Is Pablo J. Cagnoni’s new Incyte (INCY) option grant held directly or indirectly?

The filing shows the 28,475-share employee stock option is held directly by Pablo J. Cagnoni.

Does the Form 4 indicate a purchase price for the Incyte (INCY) options granted to Pablo J. Cagnoni?

The transaction reports a price of $0 for the option grant itself, with an exercise price of $106.21 per underlying share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:06 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAGNONI PABLO J

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DE 19083

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$106.21	01/16/2026		A		28,475		(1)	01/15/2036	Common Stock	28,475	$0	28,475	D

Explanation of Responses:

1. Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.